Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101
Clinical trial NCT02616055 · TERMINATED
Trial details
- NCT number
- NCT02616055
- Sponsor
- Kadmon Corporation, LLC
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-12-25
- Primary completion
- 2016-12-21
- Enrollment
- 15
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.